Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000902664-25-005038·Biodexa Pharmaceuticals Plc
Schedule 13G ownership disclosure
BIODEXA PHARMACEUTICALS PLC ADR
Ordinary Shares, nominal value 0.000001 GBP per share · CUSIP: 59564R880
Event date: 2025-06-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Cavalry Fund I LP
Shares: 0.00 · Class: 0%
- C/M CAPITAL PARTNERS, LP
Shares: 0.00 · Class: 0%
- Cavalry Investment Fund, LP
Shares: 0.00 · Class: 0%
- Cavalry Fund I Management LLC
Shares: 0.00 · Class: 0%
- Mercer Street Global Opportunity Fund, LLC
Shares: 0.00 · Class: 0%
- Mercer Street Capital Partners, LLC
Shares: 0.00 · Class: 0%
- Thomas Walsh
Shares: 0.00 · Class: 0%
- Jonathan Juchno
Shares: 0.00 · Class: 0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000902664-25-005038
- Form type
- SCHEDULE 13G/A
- Filer
- Biodexa Pharmaceuticals Plc
- CIK
- CIK 1643918
- Filed
- Nov 14, 2025
- Reporting period
- Jun 30, 2025
- Description
- Schedule 13G beneficial ownership